Skip Navigation



Annals of Oncology Advance Access published online on October 8, 2009
Annals of Oncology, doi:10.1093/annonc/mdp403
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Seruga, B.
Right arrow Articles by Tannock, I. F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seruga, B.
Right arrow Articles by Tannock, I. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Global drug development in cancer: a cross-sectional study of clinical trial registries

B. Seruga, P. C. Hertz, L. W. Le and I. F. Tannock*

Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada

* Correspondence to: Dr I. F. Tannock, Division of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9. Tel: +1-416-946-2245; Fax: +1-416-946-4563; E-mail: ian.tannock{at}uhn.on.ca

Background: Drug development in cancer is costly and may be directed toward ‘profitable’ cancers of the more developed regions (MDR) as compared with those of the less developed regions (LDR) of the world. Here, we describe drug development in relation to cancer type and geographic location.

Materials and methods: We reviewed phase II and III clinical trials evaluating new cancer drugs, which were registered from January to June 2008. Correlations were sought between the number of clinical trials and incidence, mortality and prevalence of the cancers studied (obtained from GLOBOCAN 2002) and stratified by region of the world.

Results: We identified 399 newly registered trials. Most trials (N = 229, 57%) were sponsored by industry. The most common types of cancer studied were breast 73 (18%), lung 57 (14%), prostate 44 (11%) and colorectal 28 (7%). In MDR, incidence, mortality and prevalence correlated significantly (Pearson r = 0.80, 0.73 and 0.63; P ≤ 0.01) with the number of all registered clinical trials, whereas in LDR, only prevalence showed significant association (Pearson r = 0.55; P = 0.03) with the number of trials for a given type of cancer.

Conclusion: Lethal cancers that are common in the LDR (e.g. stomach, liver and esophageal cancers) deserve greater emphasis for drug development.

cancer, drug development, global

Received for publication July 7, 2009. Accepted for publication July 10, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.